Results 231 to 240 of about 45,526 (248)

Mechanisms of resistance to imatinib mesylate in Bcr-Abl–positive leukemias

Current Opinion in Oncology, 2002
The constitutive activity of the Bcr-Abl tyrosine kinase plays a critical role in the molecular pathogenesis of not only the chronic but also the accelerated and blastic phases of chronic myelogenous leukemia. Therefore, Bcr-Abl tyrosine kinase is a rational therapeutic target in all phases of chronic myelogenous leukemia.
Ramadevi, Nimmanapalli, Kapil, Bhalla
openaire   +2 more sources

ABL-BCR expression in BCR-ABL-positive human leukemia cell lines

Leukemia Research, 1999
Expression of normal ABL and BCR and of reciprocal fusion genes BCR-ABL and ABL-BCR was examined in a panel of 53 BCR-ABL-positive cell lines by RT-PCR to determine the influence of the various transcripts on leukemogenesis. Seventeen out of 18 lymphoid cell lines expressed ABL1a and/or ABL1b, whereas only 16 out of 35 myeloid cell lines expressed one ...
C C, Uphoff, S, Habig, S, Fombonne, Y, Matsuo, H G, Drexler   +4 more
openaire   +2 more sources

Tyrosine kinase inhibitors in BCR/ABL positive ALL.

Journal of Clinical Oncology, 2011
6536 Background: The treatment of acute lymphocytic leukemia (ALL) represents a success for chemotherapy treatments developed in the early 70’s.
openaire   +1 more source

Mechanism of MK-0457 efficacy against BCR–ABL positive leukemia cells

Biochemical and Biophysical Research Communications, 2009
Mutation in the ABL kinase domain is the principal mechanism of imatinib resistance. MK-0457 is a small molecule inhibitor of the Aurora kinase family, but the mechanism of MK-0457 has not been evaluated. In this study, the gene expression profiles and intracellular signaling of chronic myeloid leukemia (CML) cell line K562 exposed to imatinib or MK ...
Seiichi, Okabe, Tetsuzo, Tauchi, Junko H, Ohyashiki, Kazuma, Ohyashiki   +3 more
openaire   +2 more sources

Activity of omacetaxine mepesuccinate against ponatinib-resistant BCR-ABL-positive cells

Blood, 2013
To the editor: Abelson murine leukemia viral oncogene homolog (ABL) tyrosine kinase inhibitors (TKIs) such as imatinib, nilotinib, and dasatinib have improved the survival of Philadelphia chromosome (Ph)-positive leukemia patients.[1][1] However, despite the impressive efficacy of these agents,
Seiichi, Okabe, Tetsuzo, Tauchi, Yuko, Tanaka, Seiichiro, Katagiri, Toshihiko, Kitahara, Kazuma, Ohyashiki   +5 more
openaire   +2 more sources

Chaperone‐rich cell lysate embedded with BCR‐ABL peptide demonstrates enhanced anti‐tumor activity against a murine BCR‐ABL positive leukemia

The FASEB Journal, 2007
Chaperone proteins are effective antitumor vaccines when purified from a tumor source, some of which are in clinical trials. Such vaccines culminate in tumor‐specific T cell responses, implicating the role of adaptive immunity. We have developed a rapid and efficient procedure utilizing an isoelectric focusing technique to obtain ...
Kerri L, Kislin, Marilyn T, Marron, Gang, Li, Michael W, Graner, Emmanuel, Katsanis   +4 more
openaire   +2 more sources

Near-hexaploid Ph-positive acute myeloid leukemia with major-BCR/ABL transcript

Cancer Genetics and Cytogenetics, 1996
We describe the first case of acute myeloid leukemia (AML) with a Philadelphia (Ph) translocation and a near-hexaploid range chromosome number, whose leukemic cells had the major-BCR/ABL transcript. The genesis of near-hexaploid leukemic cells might be due to endoreduplication of triploid leukemic cells with the Ph, since the relapsed leukemic cells ...
H, Iwama, K, Ohyashiki, J H, Ohyashiki, T, Shimamoto, T, Fujimura, K, Kawakubo, Y, Kuriyama, A, Kodama, K, Toyama   +8 more
openaire   +2 more sources

BCR/ABL-Positive Chronic Myeloid Leukemia in Children: Current Treatment Approach

Current Oncology Reports
The purpose of this review is to summarize the most updated treatment recommendations for pediatric CML, and to discuss current areas of investigation.There is new phase 1 data to support the safety of the non-ATP competitive tyrosine kinase inhibitor (TKI) asciminib in the pediatric cohort.
Jenna M, Menger, Ryan S, Sathianathen, Kathleen M, Sakamoto, Nobuko, Hijiya   +3 more
openaire   +2 more sources

Monitoring of Phosphorylated CRKL in Imatinib Resistant Patients with BCR-ABL Positive Leukemias Expressing BCR-ABL Mutants Treated with AMN107.

Blood, 2005
Abstract AMN107 is a new, highly potent and selective BCR-ABL inhibitor currently in clinical development for the treatment of imatinib-resistant chronic myelogenous leukemia (CML) or Philadelphia positive acute lymphoblastic leukemia ALL (Ph+ALL).
Andreas Hochhaus, Oliver G. Ottmann, Rüdiger Hehlmann, Peter Schuld, Leila Alland, Lydia Wunderle, Anja Binckebanck, Michael Emig, Thomas Schenk, Martin Müller, Philipp Erben, Heiko König, Thomas Ernst, Susanne Holm-Eriksen, Paul La Rosée   +14 more
openaire   +1 more source

Jumping translocation of 1q in a BCR/ABL-positive acute lymphoblastic leukemia

Cancer Genetics and Cytogenetics, 2005
Jumping translocations (JT) are rare chromosomal abnormalities in which an identical copy of a chromosomal region (donor) is translocated to a different chromosome (acceptor). Chromosome 1 is often involved as donor chromosome. JTs of the long arm of chromosome 1 (1q) or parts of it are associated with a poor outcome.
Antje-Friederike, Pelz, Gerd, Müller, Peter, Wieacker   +2 more
openaire   +2 more sources